MEDICO.NS Stock Analysis
ME
Uncovered
Medico Remedies Ltd is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Market cap $B
0.016
Dividend yield
—
Shares outstanding
82.984 B
Medico Remedies Ltd. engages in the manufacture, supply, and exportation of pharmaceutical drugs. The company is headquartered in Thane, Maharashtra. The company went IPO on 2018-02-08. The company is engaged in the manufacturing of medicines including Diuretics, Antimalarials, NSAIDS Tablets, Antireterovirals, Anti-Ulcer Drugs and Antacids Tablets. The company has manufacturing and marketing capabilities in formulation with focus on anti-infective, Beta-Lactums, cephalosporins, antimalarial, antiretroviral, anti-ulcer drugs and antacids, vitamins, haematinics and other supplements. In addition, the Company also manufactures other drugs, such as non-steroidal anti-inflammatory drugs (NSAIDS), antihistaminic, anti-diabetics, cardiovascular drugs, diuretics, anti-epileptics, combination drug kits, syrups and cream, and gel for various therapeutic segments. Its products include Doxycycline Capsules, Zenof-400 (Ofloxacin Tablets 400mg), Azithromycin Tablets, Aciclovir Tablets, Cipta Tablets, Cotrimoxazole Tablets, Tos Syrup, Paediatric Co-Trimozole Oral, Med Reactin (Cyproheptadine), and Medivit Syrup.